generationbio.com (GBIO): Long-Term Debt to Capital Ratio

DNA delivery patents and stringent FDA oversight create a powerful defensive moat for Generation Bio Co. (GBIO). The long-term debt-to-equity ratio confirms a financial strategy where the value is maintained at 0.36. Revenues are based on royalties from non-viral therapies for rare pathologies; however, the lack of sales and reliance on a single platform create extreme risks for investors.

This metric assesses the dependence of Generation Bio Co. (GBIO) on borrowed funds with maturities exceeding one year relative to its equity. The metric determines the degree of financial leverage and the balance sheet's resilience to long-term liabilities. The trend of long-term loans within the capital structure reflects the financing strategy of Generation Bio Co. (GBIO). For a developer of closed DNA platforms, a low debt level is critical during the prolonged FDA approval cycle, ensuring research autonomy without pressure from creditors.